General anesthetics

Insights Into the Anesthetics Industry, 2015-2030 - Market was Valued at $9.32 Billion in 2018 and is Expected to Decline to $9.13 Billion by 2022

Retrieved on: 
Wednesday, March 4, 2020
Anesthetic, GABAA receptor positive allosteric modulators, General anesthetics, Combination drugs, Local anesthetics, Ethers

The global anesthetics market was valued at about $9.32 billion in 2018 and is expected to decline to $9.13 billion at a CAGR of -0.5% through 2022.

Key Points: 
  • The global anesthetics market was valued at about $9.32 billion in 2018 and is expected to decline to $9.13 billion at a CAGR of -0.5% through 2022.
  • North America was the largest region in the anesthetics market in 2017, followed by Europe.
  • Stringent guidelines and regulations imposed by regulatory bodies are one of the important restraints for the anesthetics market.
  • Regulations such as these are expected to keep a check on the general anesthetic drugs market.

AMG Ketamine & Wellness Center Offers Safe, Proven Treatment for Depression, Pain and Other Conditions

Retrieved on: 
Tuesday, February 11, 2020
Alternative medicine, Pharmaceutical, Health, Mental health, Psychoactive drugs, Drugs, Neurochemistry, RTT, General anesthetics, Ketamine, Opioid, Antidepressant, Obsessive–compulsive disorder, Management of depression, Pain

The AMG Ketamine & Wellness Center, a new alternative for patients who have not found an effective treatment for depression, pain, PTSD, OCD and other conditions, has opened in Cool Springs at 1909 Mallory Lane, Suite 300 in Franklin, Tenn.

Key Points: 
  • The AMG Ketamine & Wellness Center, a new alternative for patients who have not found an effective treatment for depression, pain, PTSD, OCD and other conditions, has opened in Cool Springs at 1909 Mallory Lane, Suite 300 in Franklin, Tenn.
  • It works differently than oral medications, such as antidepressants, opioids or alternative treatments and can provide relief of symptoms in many patients within days of initiating treatment.
  • For those suffering from chronic pain, ketamine can also reduce or even eliminate their need for opioids.
  • Patients must be referred by a physician to the AMG Ketamine & Wellness Center.

Global Inhalation Anesthetics Market Analysis, Trends, and Forecasts 2019-2025 - ResearchAndMarkets.com

Retrieved on: 
Friday, January 3, 2020
Health, Pharmaceutical, General anesthetics, Branches of biology, Neurochemistry, Psychoactive drugs, NMDA receptor antagonists, GABAA receptor positive allosteric modulators, Vehicle modification, Industrial gases, Nitrous oxide, Anesthetic, Inhalational anesthetic, Inhalation

The "Inhalation Anesthetics - Market Analysis, Trends, and Forecasts" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Inhalation Anesthetics - Market Analysis, Trends, and Forecasts" report has been added to ResearchAndMarkets.com's offering.
  • The Inhalation Anesthetics market worldwide is projected to grow by US$335.4 Million, driven by a compounded growth of 3.7%.
  • Nitrous Oxide, one of the segments analyzed and sized in this study, displays the potential to grow at over 3.9%.
  • Poised to reach over US$1.1 Billion by the year 2025, Nitrous Oxide will bring in healthy gains adding significant momentum to global growth.

Global Anesthetics Market Report 2020 with Profiles of Key Players - Baxter, Abbott Laboratories, AstraZeneca, F. Hoffmann-La Roche AG, B. Braun Melsungen - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 11, 2019
Health, Pharmaceutical, Drugs, Psychoactive drugs, Neurochemistry, Anesthesia, Anesthetic, General anesthetics, NMDA receptor antagonists, Sodium channel blockers, Local anesthetic, Ketamine

The global anesthetics market was valued at about $9.32 billion in 2018 and is expected to decline to $9.13 billion at a CAGR of -0.5% through 2022.

Key Points: 
  • The global anesthetics market was valued at about $9.32 billion in 2018 and is expected to decline to $9.13 billion at a CAGR of -0.5% through 2022.
  • The anesthetics market consists of sales of drugs that cause a relaxing sensation to calm patients during surgery and remove the sensation of pain.
  • The anesthetics market is divided into general anesthetics, regional anesthetics and local anesthetics.
  • North America was the largest region in the anesthetics market in 2017, followed by Europe.

Visiongain Publishes Global Inhalation Anaesthesia Market 2019-2029 Report

Retrieved on: 
Wednesday, December 11, 2019
Medical specialties, Drugs, Psychoactive drugs, General anesthetics, NMDA receptor antagonists, Nicotinic antagonists, Anesthesia, Anesthesiology, Anesthetic, General anaesthesia, Inhalational anesthetic, Ketamine

IA has lower risk of delirium and is cost effective compared to IVA

Key Points: 
  • IA has lower risk of delirium and is cost effective compared to IVA
    Inhalational anesthesia used for sedation as well as for the induction and maintenance of general anesthesia.
  • To address the environmental impact of anesthetic gases, new technologies are being developed to scavenge them from hospital vents and recycle them.
  • These anesthetic gases contribute up to 1.0% of global carbon dioxide emissions, leading to greater environmental damage.
  • The inhalation anesthesia market is segmented on the product type, application, and geography.

Visiongain Publishes Global Inhalation Anaesthesia Market 2019-2029 Report

Retrieved on: 
Wednesday, December 11, 2019
Medical specialties, Drugs, Psychoactive drugs, General anesthetics, NMDA receptor antagonists, Nicotinic antagonists, Anesthesia, Anesthesiology, Anesthetic, General anaesthesia, Inhalational anesthetic, Ketamine

IA has lower risk of delirium and is cost effective compared to IVA

Key Points: 
  • IA has lower risk of delirium and is cost effective compared to IVA
    Inhalational anesthesia used for sedation as well as for the induction and maintenance of general anesthesia.
  • To address the environmental impact of anesthetic gases, new technologies are being developed to scavenge them from hospital vents and recycle them.
  • These anesthetic gases contribute up to 1.0% of global carbon dioxide emissions, leading to greater environmental damage.
  • The inhalation anesthesia market is segmented on the product type, application, and geography.

Relmada Therapeutics to Announce Results of Phase 2 Study of REL-1017 for Treatment Resistant Depression and Conduct Conference Call on Tuesday, October 15

Retrieved on: 
Monday, October 14, 2019
Psychoactive drugs, Drugs, Branches of biology, NMDA receptor antagonists, Glutamate, General anesthetics, Communication, Forward-looking statement, Neurotransmitters, NMDA receptor, Ketamine, N-Methyl-D-aspartic acid

NMDA receptor antagonists may have potential in the treatment of a range of psychiatric and neurological disorders associated with a variety of cognitive, neurological and behavioral symptoms.

Key Points: 
  • NMDA receptor antagonists may have potential in the treatment of a range of psychiatric and neurological disorders associated with a variety of cognitive, neurological and behavioral symptoms.
  • The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by us or on our behalf.
  • No forward-looking statement can be guaranteed and actual results may differ materially from those projected.
  • Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Pacific Ketamine Institute Introduces SPRAVATO™ Treatment for Depression and Mental Disorders

Retrieved on: 
Thursday, October 3, 2019
Psychoactive drugs, Drugs, Neurochemistry, RTT, Psychiatric diagnosis, Abnormal psychology, General anesthetics, Amines, Ketamine, Esketamine, Posttraumatic stress disorder, Management of depression

The promise of a treatment for depression that can rapidly reduce depressive symptoms in such patients has drawn widespread attention, with President Trump publicly endorsing SPRAVATO as a potential treatment for American veterans suffering from PTSD and other post-traumatic disorders.

Key Points: 
  • The promise of a treatment for depression that can rapidly reduce depressive symptoms in such patients has drawn widespread attention, with President Trump publicly endorsing SPRAVATO as a potential treatment for American veterans suffering from PTSD and other post-traumatic disorders.
  • Pacific Ketamine Institute patients have seen an 85 percent success rate with ketamine treatments administered through intravenous therapy (IV).
  • Pacific Ketamine Institute is an approved healthcare facility and pharmacy for SPRAVATO, and its experienced medical staff have the knowledge and training to safely and effectively provide ketamine-based depression treatments .
  • Pacific Ketamine Institute (PKI) is a leading clinical provider of Ketamine-based treatments for depression, PTSD, chronic pain, and bipolar mood disorders.

Isoflurane Market Insights, 2019: Analysis & Forecast on the Global & Chinese Markets to 2024 - ResearchAndMarkets.com

Retrieved on: 
Friday, September 13, 2019
Health, Pharmaceutical, Drugs, Chemistry, Neurochemistry, Ethers, GABAA receptor positive allosteric modulators, General anesthetics, Nicotinic antagonists, Organofluorides, Isoflurane, Economy of China

The "Isoflurane Market Insights 2019, Analysis and Forecast Global and Chinese Market to 2024, by Manufacturers, Product Type, Application, Regions and Technology" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Isoflurane Market Insights 2019, Analysis and Forecast Global and Chinese Market to 2024, by Manufacturers, Product Type, Application, Regions and Technology" report has been added to ResearchAndMarkets.com's offering.
  • This report is a professional and in-depth study on the current state of the global Isoflurane industry with a focus on the Chinese market.
  • Overall, the report provides an in-depth insight of 2014-2024 Global and Chinese Isoflurane market covering all important parameters.
  • Through the statistical analysis, the report depicts the Global and Chinese total market of Isoflurane industry including capacity, production, production value, cost/profit, supply/demand and Chinese import/export.

Inhalation Anesthetics Market - Growth, Trends, and Forecast (2019 - 2024)

Retrieved on: 
Wednesday, September 11, 2019
GABAA receptor positive allosteric modulators, General anesthetics, NMDA receptor antagonists, Inhalational anesthetic, Anesthetic, Medicine, Organic growth, Inhaler, Health

Increase in the number of surgeries performed globally is the major factor that is contributing to the growth of global inhalation anesthetics market.

Key Points: 
  • Increase in the number of surgeries performed globally is the major factor that is contributing to the growth of global inhalation anesthetics market.
  • However, side effects associated with the inhalation anesthetics, there is a lower adoption rate in case of inhaler anesthetics in certain surgical procedures, generic competition for almost all of the halogenated agents and recent patent expiries are restraining the inhalation anesthetics market growth.
  • Market players in Global Inhalational Anesthetics Market are focusing on the expansion of their product portfolios by adopting inorganic growth strategies such as acquisitions, mergers, and partnerships.
  • Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.